2138 results about "Carcinoma" patented technology

The invention provides systems and methods for detection, grading, scoring and tele-screening of cancerous lesions. A complete scheme for automated quantitative analysis and assessment of human and animal tissue images of several types of cancers is presented. Various aspects of the invention are directed to the detection, grading, prediction and staging of prostate cancer on serial sections / slides of prostate core images, or biopsy images. Accordingly, the invention includes a variety of sub-systems, which could be used separately or in conjunction to automatically grade cancerous regions. Each system utilizes a different approach with a different feature set. For instance, in the quantitative analysis, textural-based and morphology-based features may be extracted at image- and (or) object-levels from regions of interest. Additionally, the invention provides sub-systems and methods for accurate detection and mapping of disease in whole slide digitized images by extracting new features through integration of one or more of the above-mentioned classification systems. The invention also addresses the modeling, qualitative analysis and assessment of 3-D histopathology images which assist pathologists in visualization, evaluation and diagnosis of diseased tissue. Moreover, the invention includes systems and methods for the development of a tele-screening system in which the proposed computer-aided diagnosis (CAD) systems. In some embodiments, novel methods for image analysis (including edge detection, color mapping characterization and others) are provided for use prior to feature extraction in the proposed CAD systems.

The invention disclosed herein relates generally to immunotherapy and, more specifically, to therapeutic methods for treating tumors and cancerous tissues by first inducing necrosis or apoptosis (e.g., cryotherapy, chemotherapy, radiation therapy, ultrasound therapy, or a combination thereof applied against at least a portion of the tumor or cancerous tissue), and then delivering one or more se doses of antigen presenting cells (e.g., autologous dendritic cells) intratumourally or proximate to the tumor or cancerous tissue, but only after a selected period of time sufficient for the bioavailablity of liberated cancer-specific antigens (monitored over the selected period of time) resulting from the necrosis or apoptosis to be at or near a maximum value. The present invention provides an alternative strategy to the ex vivo loading of target antigen to antigen presenting cells such as, for example, enriched autologous dendritic cells for purposes of enhancing an immune response.

The present invention relates to methods for treating carcinomas or adenocarcinomas using at least one anti-TNF antibody.

A highly sensitive assay is disclosed which utilizes a method for gene specific primed amplification of mRNA libraries from rare cells and rare transcripts found in blood. The assay allows detection of rare mRNA (10 copies / cell) found in 1 to 10 cells isolated through immunomagnetic enrichment. The assay is an improvement over multiplex PCR and allows efficient detection of rare coding sequences for circulating carcinoma cells in the blood. The methods are useful in profiling of cells isolated from tissues or body fluids and serves as an adjunct to clinical diagnosis of diverse carcinomas including early stage detection and classification of circulating tumor cells. Monitoring of nucleic acid and protein profiles of cells either in conventional or microarray formats, facilitates management of therapeutic intervention including staging, monitoring response to therapy, confirmation of remission and detection of regression.

The apparatus, method and system for performing a high dose rate brachytherapy procedure in a body cavity may include an at least partially indwelling multi-lumen catheter with a plurality of inflatable balloons coupled thereto. A lumen may be adapted to receive radiation seeds. The balloons, when inflated, may be adapted to administer a substantially uniform radiation isodose to the body cavity. Some embodiments may be well suited to performing intrauterine brachytherapy for the treatment of endometrial carcinoma.

The present invention relates to a device for simultaneously treating a tumor or cancerous growth with both hyperthermia and X-ray radiation using brachytherapy. The device includes a needle-like introducer serving as a microwave antenna. Microwaves are emitted from the introducer to increase the temperature of cancerous body tissue. The introducer is an inner conductor of a coaxial cable. The introducer contains a hollow core which houses an X-ray emitter. The X-ray emitter is connected to a high voltage miniature cable which extends from the X-ray emitter to a high voltage power source. The X-ray emitter emits ionizing radiation to irradiate cancerous tissue. A cooling system is included to control the temperature of the introducer. Temperature sensors placed around the periphery of the tumor monitor the temperature of the treated tissue.

The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On / Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA) / shRNA agent under the control of doxycyclin (Dox) in human somatic / cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.

Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.

Devices and methods are provided for ablating areas of the gastrointestinal tract affected with certain benign, pre-cancerous, or early cancerous lesions that originate within the epithelium and are limited to the mucosal layer of the gastrointestinal tract wall. Examples of such lesions include benign conditions such as cervical inlet patch (ectopic gastric mucosa in the upper esophagus), as well as pre-cancerous and cancerous conditions such as intestinal metaplasia / intra-epithelial neoplasia / early cancer of the stomach, squamous intra-epithelial neoplasia and early cancer of the esophagus, oral and pharyngeal leukoplakia, flat colonic polyps, anal intra-epithelial neoplasia (AIN), and early cancers of the anal canal. Ablation, as provided the invention, commences at the epithelial layer of the gastrointestinal wall and penetrates deeper into the gastrointestinal wall in a controlled manner to achieve a successful patient outcome, the latter of which is defined generally as eradication of the targeted lesion, and / or a change in the targeted lesion to prevent or forestall patient morbidity. Embodiments of the device include an ablational electrode array that spans 360 degrees and an array that spans an arc of less than 360 degrees.

The present invention provides methods for preparing a stool sample in order to screen for the presence of indicators of a disease, for example a subpopulation of cancerous or precancerous cells. The methods take advantage of the recognition that cellular debris from cancerous and precancerous cells is deposited onto only a longitudinal stripe of stool as the stool is forming in the colon. Accordingly, methods of the invention comprise obtaining a representative sample, such as a circumferential or cross-sectional sample of stool in order to ensure that any disease indicator, such as cellular debris that is shed by colonic cells, is obtained in the sample.

A method and system for morphology based mitosis identification and classification of digital images. Luminance parameters such as intensity, etc. from a digital image of a biological sample (e.g., tissue cells) to which a chemical compound (e.g., a marker dye) has been applied are analyzed and corrected if necessary. Morphological parameters (e.g., size, elongation ratio, parallelism, boundary roughness, convex hull shape, etc.) from individual components within the biological sample are analyzed. A medical conclusion (e.g., type and count of mitotic cells) or a life science and biotechnology experiment conclusion is determined from the analyzed luminance and morphological parameters. The method and system may be used to develop applications for automatically obtaining a medical diagnosis (e.g., a carcinoma diagnosis).

Cancer or a precancerous condition is treated by administering a curcumin derivative to a subject.

Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology.

Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

A method and system are provided for determining a condition of a selected region of epithelial tissue. At least two current-passing electrodes are located in contact with a first surface of the selected region of the tissue. A plurality of measuring electrodes are located in contact with the first surface of the selected region of tissue as well. Electropotential and impedance are measured at one or more locations. An agent may be introduced into the region of tissue to enhance electrophysiological characteristics. The condition of the tissue is determined based on the electropotential and impedance profile at different depths of the epithelium, tissue, or organ, together with an estimate of the functional changes in the epithelium due to altered ion transport and electrophysiological properties of the tissue.

The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and / or prostate cancer.

The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).

The invention provides a formulation for a special prandial food, which contains short peptides and is provided for tumor sufferers to eat. The food uses food-originated short peptides as raw materials which are added with extracts of medical-edible Chinese herbal medicines such as champignons, dried orange peels, Chinese wolfberry, yams, tuckahoes, rhizoma polygonati, and the like, and compound complex formulation. With the food formulation, powdered or granular foods can be prepared and are dissolved with warm water to eat. The food prepared according to the formulation is easy to dissolve, can be absorbed and utilized quickly, provides a high quality nitrogen source for organisms, supplements various vitamins and minerals necessary for a human body, can correct the negative nitrogen balance of the tumor sufferers, improve the nutritional status of the tumor sufferers, and can play a role in improving organism immunity and suppressing and resisting cancers through the combined action of various factors such as bioactive components, the functional oligosaccharides, and the like in the food-originated short peptides and the extracts of the medical-edible Chinese herbal medicines, thus the food is suitable for the tumor sufferers, particularly for cancer patients who receive radiation therapy and chemotherapy to eat.

Methods and systems are provided for determining a condition of an organ, or epithelial or stromal tissue, for example in the human breast. The methods incorporate sonophoresis, the application of ultrasonic energy, in order to condition tissue for testing and enhance test measurements. A plurality of electrodes are used to measure surface and transepithelial electropotential and impedance of breast tissue at one or more locations and at several frequencies, particularly very low frequencies. An agent may be introduced into the region of tissue to enhance electrophysiological characteristics. Pressure, drugs and other agents can optionally be applied for enhanced diagnosis. Tissue condition is determined based on the electropotential and impedance profile at different depths of the epithelium, stroma, tissue, or organ, together with an estimate of the functional changes in the epithelium due to altered ion transport and electrophysiological properties of the tissue. Devices for practicing the disclosed methods are also provided.

The present invention utilizes a plurality of spectroscopic systems and methods to measure characteristics of tissue useful in the diagnosis of disease. In a preferred embodiment, a combination of fluorescence, reflectance and light scattered spectra can be measured and processed to provide biochemical, architectural and morphological state of tissue. The methods and systems can be used particularly in the early detection of carcinoma within tissue in vivo and in vitro.

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and / or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

This invention relates to methods of co-administering compounds of formula 1 which are agonists of the progesterone receptor which have the general structure: wherein: R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, with estrogen, an estrone, or an estrogen receptor agonist for contraception, hormone replacement therapy, or treating progesterone-related carcinomas and adenocarcinomas.

The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and / or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.